Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07155525

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

Led by Minia University · Updated on 2025-09-18

194

Participants Needed

1

Research Sites

165 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.

CONDITIONS

Official Title

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients scheduled for elective pancreaticoduodenectomy for malignant lesions
  • Soft pancreatic texture confirmed by surgeon palpation during surgery
  • Age between 18 and 75 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Adequate organ function defined as hemoglobin  9.0 g/dL, absolute neutrophil count  1,500/bcL, platelet count  100,000/bcL, total bilirubin  3 times upper limit of normal, alanine transaminase (ALT)  5 times upper limit of normal, serum creatinine  1.5 times upper limit of normal
  • Provided informed consent
  • Willingness to comply with study procedures and follow-up
Not Eligible

You will not qualify if you...

  • Hard pancreatic texture as assessed during surgery
  • Emergency surgery
  • Previous pancreatic surgery or pancreatic anastomosis
  • Intraoperative finding of unresectable disease
  • Known allergy to cyanoacrylate or its components
  • Pregnancy or breastfeeding
  • Active infection or sepsis
  • Inability to comply with follow-up requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Liver and GIT hospital , Minia University

Minya, Minya Governorate, Egypt, 61519

Actively Recruiting

Loading map...

Research Team

S

Saleh K Saleh, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here